A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and ...

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

Key Takeaways. Caregiver fear and availability meaningfully influence patient willingness to pursue CAR T and other immune effector therapies, contributing to persistently low uti ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...